NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Closure of Trading Window30-12-2021
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
LOSS of Share Certificate29-12-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO receives approval for the drug for the treatment of Covid-19 in India28-12-2021
Natco board approves proposal to acquire US-based pharma company
The company's board has approved to acquire Dash Pharmaceuticals through one of its subsidiary units, it said14-12-2021
NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of The Board Meeting
outcome of the Board Meeting14-12-2021
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificates13-12-2021
Natco Pharma Ltd - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Share certificates22-11-2021
Natco Pharma launches novel drug for colorectal, gastric cancer
Natco Pharma on Thursday said it has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country. The company has launched the product under the brand name Tipanat in a pack of 20 tablets in a bottle, Natco Pharma said in a regulatory filing. Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer. In India, around 1,25,000 new cases of the above-mentioned cancers are reported every year. Tipanat is of high importance in not only extending survival but also in preserving the quality of life in the late lines of treatment which is currently an unmet medical need, the drug maker said. The company said it has launched the medication at an affordable price.18-11-2021
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO launches Tipanat tablets in India, for the treatment of advanced colorectal and gastric cancer18-11-2021
Natco to step up focus on niche products products in US market
Strategy mainly focussed on products involving intricate chemistry, complex manufacturing process'17-11-2021